The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The role of alloSCT for R/R LBCL in the era of CAR-T therapy
Alberto Mussetti, MD, Catalan Institute of Oncology, Barcelona, Spain, discusses the role of allogeneic stem cell transplantation (alloSCT) in patients with large B-cell lymphoma (LBCL), highlighting its value in patients who relapse or progress after CAR-T therapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
BMS: Consultancy; Takeda: Honoraria; Gilead: Research Funding; Jazz Pharmaceuticals: Consultancy.
